Foerster Christian Uwe has made a significant move by filing a Form 3, which indicates his position as a director at Bambusa Therapeutics, Inc. This filing is crucial as it confirms his ownership of one security in the company, reflecting his stake in its future.

Bambusa Therapeutics, Inc. is a company that operates within the biological products sector. The firm is incorporated in Delaware and has its business address at 22 Boston Wharf Road, Floor 7, Boston, MA. The company is registered under the Central Index Key (CIK) number 0002044950 and is listed under the ticker symbol BBTX.

The filing states, "The undersigned hereby constitutes and appoints each of Jonathan I. Lieber and Crystal MacKay... as the undersigned's true and lawful attorney-in-fact." This indicates that Uwe has authorized these individuals to act on his behalf regarding his securities in Bambusa Therapeutics.

This development may affect the company’s governance and strategic direction, as Uwe's role as a director can influence key decisions. The biological products industry, particularly companies like Bambusa, is characterized by rapid innovation and competition, which can lead to significant shifts in market dynamics.

The filing does not say what happens next.

Details of the Filing

The Form 3 was filed on October 29, 2026, and reports that Foerster Christian Uwe is a director of Bambusa Therapeutics, Inc. The filing confirms that he owns one security in the company, which is a requirement for directors to disclose under the Securities Exchange Act of 1934.

Additionally, the filing notes that Uwe has appointed Jonathan I. Lieber and Crystal MacKay as his attorneys-in-fact, granting them the authority to act on his behalf regarding his securities. This power of attorney allows them to prepare and submit necessary reports to the SEC, including Forms 3, 4, and 5, as well as other related filings.

Company Information

Bambusa Therapeutics, Inc. is classified under the Standard Industrial Classification (SIC) code for Biological Products (No Diagnostic Substances), specifically 2836. The company is incorporated in Delaware and has a fiscal year that ends on December 31. The business is located at the same address as the reporting owner, which is 22 Boston Wharf Road, Floor 7, Boston, MA 02210.

The filing does not provide information on Uwe's background or experience, nor does it detail the specific nature of his contributions to the company as a director.